PH12020551726A1 - Treatment of atopic dermatitis - Google Patents

Treatment of atopic dermatitis

Info

Publication number
PH12020551726A1
PH12020551726A1 PH12020551726A PH12020551726A PH12020551726A1 PH 12020551726 A1 PH12020551726 A1 PH 12020551726A1 PH 12020551726 A PH12020551726 A PH 12020551726A PH 12020551726 A PH12020551726 A PH 12020551726A PH 12020551726 A1 PH12020551726 A1 PH 12020551726A1
Authority
PH
Philippines
Prior art keywords
atopic dermatitis
treatment
subject
symptoms
administering
Prior art date
Application number
PH12020551726A
Other languages
English (en)
Inventor
John Simard
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PH12020551726A1 publication Critical patent/PH12020551726A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020551726A 2018-04-24 2020-10-19 Treatment of atopic dermatitis PH12020551726A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862662055P 2018-04-24 2018-04-24
US201862730478P 2018-09-12 2018-09-12
US201862778385P 2018-12-12 2018-12-12
US201962811238P 2019-02-27 2019-02-27
PCT/US2019/028877 WO2019209923A1 (en) 2018-04-24 2019-04-24 Treatment of atopic dermatitis

Publications (1)

Publication Number Publication Date
PH12020551726A1 true PH12020551726A1 (en) 2021-07-26

Family

ID=68294274

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551726A PH12020551726A1 (en) 2018-04-24 2020-10-19 Treatment of atopic dermatitis

Country Status (10)

Country Link
US (1) US20210238273A1 (ja)
EP (1) EP3784280A4 (ja)
JP (1) JP2021527628A (ja)
CN (1) CN112105387A (ja)
AU (1) AU2019257683A1 (ja)
BR (1) BR112020021721A2 (ja)
CA (1) CA3098148A1 (ja)
MX (1) MX2020011295A (ja)
PH (1) PH12020551726A1 (ja)
WO (1) WO2019209923A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
TW202045206A (zh) * 2019-02-27 2020-12-16 美商健生生物科技公司 抗體調配物
TW202106711A (zh) * 2019-04-24 2021-02-16 美商健生生物科技公司 抗體調配物
WO2021211924A1 (en) * 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of atopic dermatitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009148575A1 (en) * 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
RU2011135768A (ru) * 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
WO2012088094A2 (en) * 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins

Also Published As

Publication number Publication date
EP3784280A4 (en) 2022-03-23
CN112105387A (zh) 2020-12-18
CA3098148A1 (en) 2019-10-31
US20210238273A1 (en) 2021-08-05
AU2019257683A1 (en) 2020-11-12
JP2021527628A (ja) 2021-10-14
BR112020021721A2 (pt) 2021-01-26
MX2020011295A (es) 2020-11-18
WO2019209923A1 (en) 2019-10-31
EP3784280A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
PH12020551726A1 (en) Treatment of atopic dermatitis
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
NZ725006A (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2021002321A (es) Nuevos metodos.
MX2021002556A (es) Tratamiento del dolor postquirurgico.
WO2012135812A3 (en) Treatment for dermatological pathologies
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2022007391A (es) Compuestos activos frente a receptores nucleares.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2021002322A (es) Nuevos metodos.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
WO2013121300A3 (en) Methods for treating psoriasis and vascular inflammation